

JURISDICTION SPECIFIC MEDICARE PART B

HEMLIBRA (emicizumab-kxwh)

POLICY

I. COVERED USES

The indications below are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn or older with hemophilia A with or without factor VIII inhibitors

All other indications will be assessed on an individual basis. Submissions for indications other than those enumerated in this policy should be accompanied by supporting evidence from Medicare approved compendia.

II. DOCUMENTATION

The following documentation must be available in a legible format with patient identification information (e.g., complete name and dates of service) and signature of physician or non-physician practitioner responsible for and providing care to the member, upon request, for all submissions:

- A. The submitted medical record must support the use of the selected ICD-10-CM codes. The submitted CPT/HCPCS code must describe the service performed.
- B. The medical record documentation must support the medical necessity of the services as stated in this policy.

III. CRITERIA FOR APPROVAL

Hemophilia A

Authorization of 12 months may be granted for treatment of hemophilia A (hereditary factor VIII deficiency).

IV. REFERENCES

1. Hemophilia Factor Products LCD (L35111) Version R16. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx>. Accessed July 1, 2020.
2. Billing and Coding: Hemophilia Factor Products (A56433) Version R2. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx>. Accessed July 1, 2020.
3. Hemlibra [package insert]. South San Francisco, CA: Genentech, Inc.; October 2018.